Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation's biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
Authors
- Efrat Luttwak (ORCID: https://orcid.org/0000-0003-0212-2135)
- Sonali M. Smith (ORCID: https://orcid.org/0000-0002-9893-4949)
- Laura Pasqualucci (ORCID: https://orcid.org/0000-0001-6819-7370)
- Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
- Loretta J. Nastoupil (ORCID: https://orcid.org/0000-0001-6071-8610)
- John P. Leonard (ORCID: https://orcid.org/0000-0002-5083-1115)
- Andrea J. Radtke (ORCID: https://orcid.org/0000-0003-4379-8967)
- Robert Kridel (ORCID: https://orcid.org/0000-0003-0287-7124)
- Meghan Gutierrez
- Philippe A. Armand (ORCID: https://orcid.org/0000-0001-6098-1603)
- Matthew J. Maurer (ORCID: https://orcid.org/0000-0002-1867-0526)
- Stephen M. Ansell (ORCID: https://orcid.org/0000-0003-1244-6758)
- Michael Richard Green (ORCID: https://orcid.org/0000-0001-6309-9472)
- Andrew David Zelenetz (ORCID: https://orcid.org/0000-0003-1403-6883)
- Carla Casulo (ORCID: https://orcid.org/0000-0003-4998-9932)
- Reid W. Merryman (ORCID: https://orcid.org/0000-0002-6360-3234)
- John M. Timmerman (ORCID: https://orcid.org/0000-0003-4104-8943)
- Brad S. Kahl (ORCID: https://orcid.org/0000-0003-0459-6609)
- James R. Cerhan (ORCID: https://orcid.org/0000-0002-7482-178X)
- Brian K. Link (ORCID: https://orcid.org/0000-0001-5084-0698)
- Ann Steward LaCasce (ORCID: https://orcid.org/0000-0001-7349-0176)
- Gilles Salles (ORCID: https://orcid.org/0000-0002-9541-8666)
- Sarah C. Rutherford (ORCID: https://orcid.org/0000-0002-1064-7727)
- Wendy Béguelin (ORCID: https://orcid.org/0000-0002-4894-9229)
- Bertrand Nadel
Institutions
- University of Iowa (US)
- Centre National de la Recherche Scientifique (FR)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- Oracle (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of British Columbia (CA)
- Inserm (FR)
- Washington University in St. Louis (US)
- Cornell University (US)
- New York Hospital Queens (US)
- UCLA Medical Center (US)
- Spinal Cord Injury BC (CA)
- Princess Margaret Cancer Centre (CA)
- University of Rochester Medical Center (US)
- University of Chicago (US)
- Presbyterian Hospital (US)
- Los Angeles Medical Center (US)
- Southwest Women's Oncology (US)
- Dana-Farber Cancer Institute (US)
- Lymphoma Research Foundation (US)
- Vistec Electron Beam (Germany) (DE)
- Centre d’Immunologie de Marseille-Luminy (FR)
- Mercy Regional Medical Center (US)
- Mayo Clinic in Florida (US)
- Weill Cornell Medicine (US)
- University of Rochester (US)
- New York University (US)
- Columbia University (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1182/bloodadvances.2025018079
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leukemia and Lymphoma Society
- Gilead Sciences
- Celgene
- Regeneron Pharmaceuticals
- BeiGene
- Incyte
- MorphoSys
- Ipsen
- National Institutes of Health
- Genentech
- Pharmacyclics
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- Daiichi Sankyo Europe